{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:59:50Z","timestamp":1790269190819,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04960-3","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:02:06Z","timestamp":1790265726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4\/6 inhibitor therapy"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5997-0373","authenticated-orcid":false,"given":"Tu\u011fba","family":"\u00d6nder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zt\u00fcrk","family":"Ate\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Emin","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe Ocak","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"20","key":"4960_CR1","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925\u20131936","journal-title":"N Engl J Med"},{"issue":"18","key":"4960_CR2","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):1738\u20131748","journal-title":"N Engl J Med"},{"issue":"3","key":"4960_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/14737140.2021.1852934","volume":"21","author":"CE Onesti","year":"2021","unstructured":"Onesti CE, Jerusalem G (2021) CDK4\/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Rev Anticancer Ther 21(3):283\u2013298","journal-title":"Expert Rev Anticancer Ther"},{"key":"4960_CR4","doi-asserted-by":"publisher","first-page":"102086","DOI":"10.1016\/j.ctrv.2020.102086","volume":"90","author":"A Desnoyers","year":"2020","unstructured":"Desnoyers A et al (2020) Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4\/6 inhibitors in metastatic breast cancer: A network meta-analysis. Cancer Treat Rev 90:102086","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"4960_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1053\/j.seminoncol.2024.01.002","volume":"50","author":"D Wekking","year":"2023","unstructured":"Wekking D et al (2023) CDK4\/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety. Semin Oncol 50(6):131\u2013139","journal-title":"Semin Oncol"},{"issue":"1","key":"4960_CR6","doi-asserted-by":"publisher","first-page":"2557509","DOI":"10.1080\/07853890.2025.2557509","volume":"57","author":"HY Wu","year":"2025","unstructured":"Wu HY et al (2025) Treatment consequence and adverse events of cyclin-dependent kinase 4\/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis. Ann Med 57(1):2557509","journal-title":"Ann Med"},{"issue":"7","key":"4960_CR7","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/14740338.2025.2465852","volume":"25","author":"X Tian","year":"2026","unstructured":"Tian X et al (2026) Adverse event profiles of CDK4\/6 inhibitors: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database. Expert Opin Drug Saf 25(7):1329\u20131339","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"4960_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13058-020-01263-0","volume":"22","author":"J Ettl","year":"2020","unstructured":"Ettl J et al (2020) Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Breast Cancer Res 22(1):27","journal-title":"Breast Cancer Res"},{"issue":"10","key":"4960_CR9","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1634\/theoncologist.2016-0097","volume":"21","author":"S Verma","year":"2016","unstructured":"Verma S et al (2016) Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive\/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). Oncologist 21(10):1165\u20131175","journal-title":"Oncologist"},{"issue":"12","key":"4960_CR10","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1634\/theoncologist.2019-0019","volume":"24","author":"V Dieras","year":"2019","unstructured":"Dieras V et al (2019) Palbociclib with Letrozole in Postmenopausal Women with ER+\/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. Oncologist 24(12):1514\u20131525","journal-title":"Oncologist"},{"issue":"12","key":"4960_CR11","doi-asserted-by":"publisher","first-page":"662","DOI":"10.31083\/ph.2020.0761","volume":"75","author":"M Kimura","year":"2020","unstructured":"Kimura M, Usami E, Yoshimura T (2020) Association between severe neutropenia and progression-free survival in patients with advanced or recurrent breast cancer treated with palbociclib. Pharmazie 75(12):662\u2013665","journal-title":"Pharmazie"},{"issue":"6","key":"4960_CR12","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41416-020-0967-7","volume":"123","author":"NP McAndrew","year":"2020","unstructured":"McAndrew NP et al (2020) Early treatment-related neutropenia predicts response to palbociclib. Br J Cancer 123(6):912\u2013918","journal-title":"Br J Cancer"},{"issue":"1","key":"4960_CR13","first-page":"8994954","volume":"2023","author":"K Elnaghi","year":"2023","unstructured":"Elnaghi K et al (2023) Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome. Breast J 2023(1):8994954","journal-title":"Breast J"},{"issue":"1","key":"4960_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/1120009X.2024.2330835","volume":"37","author":"HC Yildirim","year":"2025","unstructured":"Yildirim HC et al (2025) Efficacy of first-line CDK 4\u20136 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study. J Chemother 37(1):69\u201375","journal-title":"J Chemother"},{"issue":"1","key":"4960_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11523-020-00771-5","volume":"16","author":"J Zheng","year":"2021","unstructured":"Zheng J et al (2021) Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib. Target Oncol 16(1):69\u201376","journal-title":"Target Oncol"},{"issue":"3","key":"4960_CR16","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3390\/curroncol29030145","volume":"29","author":"F Fu","year":"2022","unstructured":"Fu F et al (2022) The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer. Curr Oncol 29(3):1761\u20131772","journal-title":"Curr Oncol"},{"key":"4960_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.breast.2021.11.013","volume":"60","author":"RK Ismail","year":"2021","unstructured":"Ismail RK et al (2021) Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer. Breast 60:263\u2013271","journal-title":"Breast"},{"issue":"7","key":"4960_CR18","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1177\/10781552221144280","volume":"29","author":"C Fernandez-Cuerva","year":"2023","unstructured":"Fernandez-Cuerva C, Chinchilla-Alarcon T, Alcaraz-Sanchez JJ (2023) Real-world effectiveness of ribociclib in metastatic breast cancer patients: Does dose affect survival? J Oncol Pharm Pract 29(7):1619\u20131627","journal-title":"J Oncol Pharm Pract"},{"key":"4960_CR19","first-page":"100691","volume":"35","author":"MQN Hackert","year":"2023","unstructured":"Hackert MQN et al (2023) Real-world palbociclib effectiveness in patients with metastatic breast cancer: Focus on neutropenia-related treatment modification strategies and clinical outcomes. Cancer Treat Res Commun 35:100691","journal-title":"Cancer Treat Res Commun"},{"issue":"5","key":"4960_CR20","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41416-021-01415-9","volume":"125","author":"HA Burris","year":"2021","unstructured":"Burris HA et al (2021) Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and \u2013\u20097 trials in hormone receptor-positive, HER2-negative advanced breast cancer. Br J Cancer 125(5):679\u2013686","journal-title":"Br J Cancer"},{"issue":"12","key":"4960_CR21","doi-asserted-by":"publisher","first-page":"7426","DOI":"10.3390\/curroncol31120548","volume":"31","author":"P Kubilay Tolunay","year":"2024","unstructured":"Kubilay Tolunay P et al (2024) Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4\/6 Inhibitors. Curr Oncol 31(12):7426\u20137436","journal-title":"Curr Oncol"},{"issue":"2","key":"4960_CR22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10549-020-05793-1","volume":"183","author":"B Moftakhar","year":"2020","unstructured":"Moftakhar B et al (2020) Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer. Breast Cancer Res Treat 183(2):411\u2013418","journal-title":"Breast Cancer Res Treat"},{"key":"4960_CR23","doi-asserted-by":"publisher","first-page":"103950","DOI":"10.1016\/j.clon.2025.103950","volume":"48","author":"F Petrelli","year":"2025","unstructured":"Petrelli F, Ghidini A, Dottorini L (2025) Association Between Dose Reduction of Cyclin-dependent Kinase 4\/6 Inhibitors and Survival in Advanced Breast Cancer: A Systematic Review and Meta-analysis. Clin Oncol (R Coll Radiol) 48:103950","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"4960_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/10781552211050106","volume":"29","author":"C Olazagasti","year":"2023","unstructured":"Olazagasti C et al (2023) A deep dive into CDK4\/6 inhibitors: Evaluating real world toxicities and treatment paradigms in the elderly population. J Oncol Pharm Pract 29(1):14\u201321","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"4960_CR25","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10549-021-06215-6","volume":"188","author":"KB Kristensen","year":"2021","unstructured":"Kristensen KB et al (2021) Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2- metastatic breast cancer. Breast Cancer Res Treat 188(3):799\u2013809","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"4960_CR26","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/14737140.2025.2490289","volume":"25","author":"F Ceylan","year":"2025","unstructured":"Ceylan F et al (2025) The effect of dose reduction of CDK4\/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer. Expert Rev Anticancer Ther 25(5):579\u2013588","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"4960_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00280-025-04836-y","volume":"95","author":"M Catalano","year":"2025","unstructured":"Catalano M et al (2025) Impact of adverse events on survival outcomes in patients treated with CDK4\/6 inhibitors for advanced breast cancer. Cancer Chemother Pharmacol 95(1):117","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"4960_CR28","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1177\/10781552221117135","volume":"29","author":"F Musicco","year":"2023","unstructured":"Musicco F et al (2023) A multicentre study with real-world data of the use of palbociclib in the treatment of breast cancer: Treatment duration correlates with dose reductions. J Oncol Pharm Pract 29(8):1806\u20131815","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"4960_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s44276-024-00108-z","volume":"2","author":"A Bjerrum","year":"2024","unstructured":"Bjerrum A et al (2024) Overall survival after CDK4\/6 inhibitor dose reduction in women with metastatic breast cancer. BJC Rep 2(1):82","journal-title":"BJC Rep"},{"issue":"1","key":"4960_CR30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/ijc.70433","volume":"159","author":"P Marschner","year":"2026","unstructured":"Marschner P et al (2026) Prediction of dose reductions and impact of reduced starting doses of CDK4\/6i on effectiveness in HR-positive\/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry. Int J Cancer 159(1):244\u2013256","journal-title":"Int J Cancer"},{"issue":"3","key":"4960_CR31","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10549-019-05181-4","volume":"175","author":"K Clifton","year":"2019","unstructured":"Clifton K et al (2019) Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population. Breast Cancer Res Treat 175(3):667\u2013674","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"4960_CR32","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s00432-025-06336-1","volume":"151","author":"N Ilhan","year":"2025","unstructured":"Ilhan N et al (2025) Management of hepatotoxicity associated with CDK4\/6 inhibitors and rechallenge strategies in metastatic hormone-positive, HER2-NEGATIVE BREAST CANCER. J Cancer Res Clin Oncol 151(10):270","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"4960_CR33","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1186\/s12885-025-15181-x","volume":"25","author":"O Bas","year":"2025","unstructured":"Bas O et al (2025) Real-world evidence of ribociclib-induced hepatotoxicity in patients with breast cancer: a multi-center experience. BMC Cancer 25(1):1831","journal-title":"BMC Cancer"},{"issue":"12","key":"4960_CR34","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F et al (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31(12):1623\u20131649","journal-title":"Ann Oncol"},{"issue":"5","key":"4960_CR35","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.18.01160","volume":"37","author":"HJ Burstein","year":"2019","unstructured":"Burstein HJ et al (2019) Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol 37(5):423\u2013438","journal-title":"J Clin Oncol"},{"key":"4960_CR36","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","author":"National Cancer Institute","year":"2017","unstructured":"National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S. Department of Health and Human Services; National Institutes of Health, Bethesda, MD"},{"key":"4960_CR37","doi-asserted-by":"crossref","unstructured":"Rugo HS et al (2021) Management of abemaciclib-associated adverse events in patients with hormone receptor\u2010positive, human epidermal growth factor receptor 2\u2010negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. The oncologist. 26(1):e53\u2013e65","DOI":"10.1002\/onco.13531"},{"issue":"9","key":"4960_CR38","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0142","volume":"22","author":"LM Spring","year":"2017","unstructured":"Spring LM et al (2017) Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4\/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Oncologist 22(9):1039\u20131048","journal-title":"Oncologist"},{"issue":"4","key":"4960_CR39","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.4143\/crt.2022.1543","volume":"55","author":"SG Kim","year":"2023","unstructured":"Kim SG et al (2023) Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer. Cancer Res Treat 55(4):1198\u20131209","journal-title":"Cancer Res Treat"},{"issue":"6","key":"4960_CR40","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41416-020-0967-7","volume":"123","author":"NP McAndrew","year":"2020","unstructured":"McAndrew NP et al (2020) Early treatment-related neutropenia predicts response to palbociclib. Br J Cancer 123(6):912","journal-title":"Br J Cancer"},{"issue":"8","key":"4960_CR41","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1248\/bpb.b23-00187","volume":"46","author":"S Takada","year":"2023","unstructured":"Takada S et al (2023) Real-World Predictors of Severe Neutropenia Associated with Palbociclib and Endocrine Therapy for Metastatic Breast Cancer in Japanese Patients. Biol Pharm Bull 46(8):1105\u20131111","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"4960_CR42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10549-020-05750-y","volume":"183","author":"A Ham","year":"2020","unstructured":"Ham A et al (2020) Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer. Breast Cancer Res Treat 183(1):107\u2013116","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4960_CR43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41523-024-00657-z","volume":"10","author":"S Scagnoli","year":"2024","unstructured":"Scagnoli S et al (2024) Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study. NPJ Breast Cancer 10(1):58","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"4960_CR44","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/tbj.14195","volume":"27","author":"FR Ogliari","year":"2021","unstructured":"Ogliari FR et al (2021) Predictive variables of palbociclib dose reduction and its impact on survival outcomes: A retrospective bicentric study. Breast J 27(4):415\u2013416","journal-title":"Breast J"},{"issue":"12","key":"4960_CR45","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/jcph.2310","volume":"63","author":"Y Ji","year":"2023","unstructured":"Ji Y et al (2023) Quantitative Assessment of Ribociclib Exposure-Response Relationship to Justify Dose Regimen in Patients with Advanced Breast Cancer. J Clin Pharmacol 63(12):1359\u20131370","journal-title":"J Clin Pharmacol"},{"key":"4960_CR46","doi-asserted-by":"publisher","first-page":"175883591879332","DOI":"10.1177\/1758835918793326","volume":"10","author":"M Thill","year":"2018","unstructured":"Thill M, Schmidt M (2018) Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol 10:1758835918793326","journal-title":"Ther Adv Med Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04960-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04960-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04960-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:02:12Z","timestamp":1790265732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04960-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4960"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04960-3","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"23 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Ethics Committee of the Health Sciences University, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital. In accordance with national legislation and institutional policies, the requirement for written informed consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"110"}}